TY - JOUR T1 - Antiretroviral pre-exposure prophylaxis for HIV prevention is highly effective in community settings JF - Evidence Based Medicine JO - Evid Based Med SP - 99 LP - 99 DO - 10.1136/ebmed-2016-110403 VL - 21 IS - 3 AU - Angela Robertson Bazzi Y1 - 2016/06/01 UR - http://ebm.bmj.com/content/21/3/99.abstract N2 - Commentary on: McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016;387:53–60.OpenUrlCrossRefPubMedRandomised placebo-controlled trials have demonstrated the efficacy of antiretroviral pre-exposure prophylaxis (PrEP) in preventing HIV-1 acquisition in diverse international populations including men who have sex with men (MSM).1–3 However, concerns regarding adherence to daily regimens and potential risk compensation (eg, increased engagement in condomless sex) in real-world settings have contributed to skepticism and delayed implementation of PrEP. The PROUD open-label randomised pilot trial tested the effectiveness of daily oral PrEP delivered to high-risk MSM through 13 sexual health … ER -